A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients [PDF]
Frontiers in PharmacologyIntroduction:Current clinical research has reported the effectiveness and safety of venetoclax in combination with hypomethylating agents (VEN-HMA) in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).
Pan Deng, Yan Xiaojing, Yue Pengjie
exaly +4 more sources
Hypomethylating Agents in Oncohematology [PDF]
Клиническая онкогематология, 2016 The review describes epigenetic processes, including methylation of nuclear and mitochondrial DNA, as well as RNA. It dwells on mechanisms of demethylation and corresponding medicinal products.
Anton Dmitrievich Shirin +1 more
doaj +2 more sources
Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromes [PDF]
HaematologicaNot available.
Mahmood Aldapt +21 more
doaj +2 more sources
Immunological effects of hypomethylating agents [PDF]
Expert Review of Hematology, 2017 Epigenetic changes resulting from aberrant methylation patterns are a recurrent observation in hematologic malignancies. Hypomethylating agents have a well-established role in the management of patients with high-risk myelodysplastic syndrome or acute myeloid leukemia.
Meghali Goswami, Christopher Hourigan
exaly +3 more sources
Clinical update on hypomethylating agents [PDF]
International Journal of Hematology, 2019 Hypomethylating agents (HMAs), azacitidine and decitabine, are standards of care in higher-risk myelodysplastic syndromes and in acute myeloid leukemia patients ineligible for intensive therapy. Over the last 10 years, research efforts have sought to better understand their mechanism of action, both at the molecular and cellular level.
Raphaël Itzykson +2 more
exaly +3 more sources
Hypomethylating agents increase L1 retroelement expression without inducing novel insertions in myeloid malignancies [PDF]
Molecular OncologyRetroelements in the human genome are silenced via multiple mechanisms, including DNA methylation, to prevent their potential mutagenic effect. Retroelement activity, demonstrated by their expression and somatic retrotransposition events, was shown to be
Šárka Pavlová +14 more
doaj +2 more sources
Fixed-time treatment of elderly patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) using hypomethylating agents and venetoclax – a case series [PDF]
Annals of HematologyStandard therapy for elderly patients with acute myeloid leukemia (AML) consists of hypomethylating agents (HMAs) combined with venetoclax (VEN), administered long term until disease progression.
Albrecht Lindemann +2 more
doaj +2 more sources
Multi-Organ Adverse Reaction to Two Hypomethylating Agents: A Challenge in High-Risk Myelodysplastic Syndrome Treatment [PDF]
Hematology ReportsBackground and Clinical Significance: Intermediate- to high-risk Myelodysplastic Syndrome (MDS), according to the Revised International Prognostic Scoring System (IPSS-M), confers a high risk of progression into acute myeloid leukemia.
Sofia Brites Alves +1 more
doaj +2 more sources
Meta-analysis on hypomethylating agents in myelodysplastic syndromes
Haematologica, 2010 The addition of hypomethylating agents into the armatorium against myelodysplastic syndromes (MDS) is commonly accepted as a promising new therapeutic option in this otherwise frustrating field.
Christine Herbst +2 more
doaj +3 more sources
A real-world data study on long-course venetoclax combined with hypomethylating agents in unfit patients [PDF]
Frontiers in OncologyThis study aimed to investigate the efficacy, safety and prognostic value of measurable residual disease (MRD) in unfit AML patients treated with long-course venetoclax combined with hypomethylating agents, so as to provide evidence for optimizing ...
Chen Cao +8 more
doaj +2 more sources